Does sumatriptan cross the blood-brain barrier in animals and man?

被引：52
作者：
Tfelt-Hansen, Peer Carsten [1 ]
机构：
[1] Univ Copenhagen, Glostrup Hosp, Danish Headache Ctr, Dept Neurol,Fac Hlth Sci, DK-2600 Copenhagen, Denmark
来源：
JOURNAL OF HEADACHE AND PAIN | 2010年 / 11卷 / 01期
关键词：
Blood-brain barrier; Sumatriptan; Migraine; CNS; Animal studies; Human studies; TRIGEMINAL NUCLEUS CAUDALIS; CORTICAL SPREADING DEPRESSION; AGONIST ZOLMITRIPTAN 311C90; C-FOS EXPRESSION; MIGRAINE ATTACK; PLASMA EXTRAVASATION; ANTIMIGRAINE ACTION; RECEPTOR AGONIST; STEM ACTIVATION; MESSENGER-RNA;
D O I：
10.1007/s10194-009-0170-y
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Sumatriptan, a relatively hydrophilic triptan, based on several animal studies has been regarded to be unable to cross the blood-brain barrier (BBB). In more recent animal studies there are strong indications that sumatriptan to some extent can cross the BBB. The CNS adverse events of sumatriptan in migraine patients and normal volunteers also indicate a more general effect of sumatriptan on CNS indicating that the drug can cross the BBB in man. It has been discussed whether a defect in the BBB during migraine attacks could be responsible for a possible central effect of sumatriptan in migraine. This review suggests that there is no need for a breakdown in the BBB to occur in order to explain a possible central CNS effect of sumatriptan.
引用
收藏
页码：5 / 12
页数：8
相关论文
共 74 条
[1]   A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate [J].
Afridi, SK ;
Matharu, MS ;
Lee, L ;
Kaube, H ;
Friston, KJ ;
Frackowiak, RSJ ;
Goadsby, PJ .
BRAIN, 2005, 128 :932-939
[2]   Where do triptans act in the treatment of migraine? [J].
Ahn, AH ;
Basbaum, AI .
PAIN, 2005, 115 (1-2) :1-4
[3]  
[Anonymous], 2006, HEADACHES
[4]   Acute pathological laughter induced by sumatriptan [J].
Barbanti, P. ;
Fabbrini, G. ;
Berardelli, A. .
CEPHALALGIA, 2008, 28 (01) :92-93
[5]  
BATES EA, 2009, CEPHALALGIA IN PRESS
[6]   5HT1B and 5HT1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion [J].
Bonaventure, P ;
Voorn, P ;
Luyten, WHML ;
Leysen, JE .
NEUROREPORT, 1998, 9 (04) :641-645
[7]   THE ANTIMIGRAINE DRUG, SUMATRIPTAN (GR43175), SELECTIVELY BLOCKS NEUROGENIC PLASMA EXTRAVASATION FROM BLOOD-VESSELS IN DURA MATER [J].
BUZZI, MG ;
MOSKOWITZ, MA .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (01) :202-206
[8]   TREATMENT OF ACUTE MIGRAINE WITH SUBCUTANEOUS SUMATRIPTAN [J].
CADY, RK ;
WENDT, JK ;
KIRCHNER, JR ;
SARGENT, JD ;
ROTHROCK, JF ;
SKAGGS, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (21) :2831-2835
[9]   Differential distribution of [H-3]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: Focus on brainstem and spinal cord [J].
Castro, ME ;
Pascual, J ;
Romon, T ;
DelArco, C ;
DelOlmo, E ;
Pazos, A .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :535-542
[10]   Rizatriptan has central antinociceptive effects against durally evoked responses [J].
Cumberbatch, MJ ;
Hill, RG ;
Hargreaves, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (01) :37-40
12345678